Ironvine Capital Partners LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,788 shares of the medical research company's stock after selling 2,297 shares during the quarter. Thermo Fisher Scientific accounts for approximately 2.7% of Ironvine Capital Partners LLC's portfolio, making the stock its 14th largest holding. Ironvine Capital Partners LLC's holdings in Thermo Fisher Scientific were worth $30,978,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of TMO. J. Stern & Co. LLP grew its position in Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $15,501,867,000. Corient Private Wealth LP bought a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $382,547,000. Norges Bank bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at $3,072,744,000. Finally, Bank of New York Mellon Corp purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $1,974,561,000. Institutional investors own 89.23% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the stock. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a research report on Friday, May 8th. Royal Bank Of Canada raised their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research note on Friday, July 24th. Morgan Stanley upped their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. KeyCorp reiterated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $619.41.
Check Out Our Latest Stock Report on Thermo Fisher Scientific
Insider Buying and Selling at Thermo Fisher Scientific
In related news, VP Lisa P. Britt sold 11,440 shares of the business's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company's stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Price Performance
TMO stock opened at $600.32 on Wednesday. The firm has a 50-day moving average of $564.35 and a 200 day moving average of $512.92. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market cap of $221.97 billion, a P/E ratio of 32.29, a PEG ratio of 2.58 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.
Thermo Fisher Scientific Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
